Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
NCT ID: NCT00600756
Last Updated: 2012-10-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
798 participants
INTERVENTIONAL
2008-01-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quetiapine XR
Quetiapine XR
Oral, once daily, tablets of 400 mg to 800 mg
Risperidone
Risperidone
Oral, once daily, tablets of 2 mg to 6 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine XR
Oral, once daily, tablets of 400 mg to 800 mg
Risperidone
Oral, once daily, tablets of 2 mg to 6 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with first episode of the above mentioned disease (item 3) or patient requiring a medication change for clinical reasons (effectiveness, tolerability, compliance, patient preference), i.e. switch from typical to atypical neuroleptics, switch from other atypical neuroleptics, excluding patients treated with risperidone or quetiapine at the time of enrolment.
Exclusion Criteria
* Patients with previous treatment with risperidone or quetiapine may be enrolled if change of treatment has not been dictated by major lack of tolerability and efficacy and if date of last dose has been at least 3 months prior to enrolment.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Brecher, MSD
Role: STUDY_DIRECTOR
AstraZeneca
Prof Naber, MD
Role: PRINCIPAL_INVESTIGATOR
Klinikum Eppendorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Assebroek, Belgium, Belgium
Research Site
Hasselt, Belgium, Belgium
Research Site
Liège, Belgium, Belgium
Research Site
Montignies-sur-Sambre, Belgium, Belgium
Research Site
Roeselare, Belgium, Belgium
Research Site
Sint-Denijs-Westrem, , Belgium
Research Site
Tournai, , Belgium
Research Site
Fortaleza, Ceará, Brazil
Research Site
Salvador, Estado de Bahia, Brazil
Research Site
Aparecida de Goiânia, Goiás, Brazil
Research Site
Belo Horizonte, Minas Gerais, Brazil
Research Site
Curitiba, Paraná, Brazil
Research Site
Recife, Pernambuco, Brazil
Research Site
Rio de Janeiro, Rio de Janeiro, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
Itapira, São Paulo, Brazil
Research Site
Ribeirão Preto, São Paulo, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Sorocaba, São Paulo, Brazil
Research Site
Botucatu, , Brazil
Research Site
Cerova Koria Village, Veliko Tarnovo, Bulgaria
Research Site
Pazardzhik, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Stara Zagora, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Barrio Los Yoses, Provincia de San José, Costa Rica
Research Site
Curridabat, Provincia de San José, Costa Rica
Research Site
Guadalupe, Provincia de San José, Costa Rica
Research Site
Helsinki, , Finland
Research Site
Kitee, , Finland
Research Site
Kuopio, , Finland
Research Site
Lapua, , Finland
Research Site
Pori, , Finland
Research Site
Raahe, , Finland
Research Site
Rovaniemi, , Finland
Research Site
Tampere, , Finland
Research Site
Turku, , Finland
Research Site
Bad Saarow, , Germany
Research Site
Berlin, , Germany
Research Site
Bielefeld, , Germany
Research Site
Bochum, , Germany
Research Site
Butzbach, , Germany
Research Site
Cologne, , Germany
Research Site
Darmstadt, , Germany
Research Site
Duisburg, , Germany
Research Site
Gelsenkirchen, , Germany
Research Site
Grevenbroich, , Germany
Research Site
Hamburg, , Germany
Research Site
Hattingen, , Germany
Research Site
Hildesheim, , Germany
Research Site
Königsbrück, , Germany
Research Site
Mittweida, , Germany
Research Site
München, , Germany
Research Site
Oranienburg, , Germany
Research Site
Siegen, , Germany
Research Site
Stralsund, , Germany
Research Site
Wismar, , Germany
Research Site
Andria, BA, Italy
Research Site
Feltre, BL, Italy
Research Site
Maddaloni, CE, Italy
Research Site
Sora, FR, Italy
Research Site
Genova, GE, Italy
Research Site
Milan, MI, Italy
Research Site
Perugia, PG, Italy
Research Site
Fidenza, PR, Italy
Research Site
Parma, PR, Italy
Research Site
Palmi, RC, Italy
Research Site
Rimini, RN, Italy
Research Site
Salerno, SA, Italy
Research Site
Sassari, SS, Italy
Research Site
Chioggia, VE, Italy
Research Site
Ancona, , Italy
Research Site
Pompei, , Italy
Research Site
México, D.f., Mexico
Research Site
México, D.F, Mexico
Research Site
Monterrey, Nuevo Leon, Mexico, Mexico
Research Site
San Luis Potosí City, San Luis Potosí, Mexico
Research Site
Guadalajara Jalisco, , Mexico
Research Site
México, , Mexico
Research Site
Yucatán, , Mexico
Research Site
Abraveses, , Portugal
Research Site
Braga, , Portugal
Research Site
Coimbra, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Porto, , Portugal
Research Site
Santarém, , Portugal
Research Site
Piteşti, Argeş, Romania
Research Site
Galati, Galați County, Romania
Research Site
Bucharest, , Romania
Research Site
Craiova, , Romania
Research Site
Sibiu, , Romania
Research Site
Moscow, Russia, Russia
Research Site
Kazan', , Russia
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Jaén, Andalusia, Spain
Research Site
Málaga, Andalusia, Spain
Research Site
Seville, Andalusia, Spain
Research Site
Zamudio (vizcaya), Basque Country, Spain
Research Site
Salamanca, Castille and León, Spain
Research Site
Zamora, Castille and León, Spain
Research Site
Mataro (barcelona), Catalonia, Spain
Research Site
Vigo, Galicia, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Langreo, Principality of Asturias, Spain
Research Site
Elche (alicante), Valencia, Spain
Research Site
Sant Joan d'Alacant, Valencia, Spain
Research Site
Prilly, Canton of Vaud, Switzerland
Research Site
Wil, , Switzerland
Research Site
Istanbul, Turkey, Turkey (Türkiye)
Research Site
Manisa, Turkey, Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Elâzığ, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Naber D, Peuskens J, Schwarzmann N, Goltz M, Kruger H, Lambert M, Haro JM. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). Eur Neuropsychopharmacol. 2013 Oct;23(10):1257-69. doi: 10.1016/j.euroneuro.2013.07.006. Epub 2013 Jul 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1443L00039
Identifier Type: -
Identifier Source: org_study_id